Metagenomi

Update in progress

MGX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Metagenomi Therapeutics, Inc. is an in vivo genome editing company focused on developing curative genetic medicines in the United States. Its lead program, MGX-001, aims to provide lifelong protection from bleeding and joint damage in people with hemophilia. It collaborates with Ionis Pharmaceuticals on ApoC-III for hypertriglyceridemia, TTR for transthyretin amyloidosis, AGT for refractory hypertension, and other programs. Formerly Metagenomi, Inc., it renamed in January 2026. Founded in 2016 and headquartered in Emeryville, California.

Company score

Sentiment: -0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.18; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.35; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive